This technology includes a novel application of chimeric monoclonal antibodies (i.e.animal-human) as substitutes for patient /organism specimens to create standardized training (TP), proficiency testing (PT), quality control (QC), lot-to-lot validation, and new serologic test evaluation and validation panels to support the implementation of quality management systems (QMS) of serology-based tests.
This technology includes Escherichia coli isolate with MCR-1 gene which can be used in the development of diagnostic tests. The MCR-1 gene makes bacteria resistant to the antibiotic colistin, which is used as a last-resort drug to treat patients with multi-drug-resistant infections, including carbapenem-resistant Enterobacteriaceae (CRE). This gene exists on a plasmid, a small piece of DNA that is capable of moving from one bacterium to another, spreading antibiotic resistance among bacterial species.
This technology includes a novel, isolated reassortant mammalian Orthoreovirus (MRV) isolated from pigs with neurological symptoms, for use in the development of vaccines and diagnostic tests. This isolate has S1 gene from MRV1 closed to bovine isolated, M2 gene from MRV2 and other 8 genes from MRV3 based on full-genome sequence analysis. MRV3 has been reported and isolated from the US pigs with diarrhea symptom. Compared to the reported swine MRV3 isolates that cause diarrhea in pigs, the novel reassortant MRV causes neurological disease in pigs.
The NIH Technology Transfer Program has won the Licensing Executive Society’s Deals of Distinction award for 2022. The Deals of Distinction Award is given to an outstanding licensing deal from the past year. Steve Ferguson, Special Advisor at the NIH Office of Technology Transfer, recently attended the LES award ceremony to accept the award on NIH’s behalf. Continue reading to learn about this award-winning license agreement from Steve himself.
NIAID TTIPO’s extraordinary efforts in “COVID-19 Technologies Licensed Globally Through WHO Program” was recognized by the Licensing Executives Society (U.S.A. & Canada) in 2022 with a Deals of Distinction Award in the Industry-University-Government Interface Sector. This award acknowledged the collaborative efforts put forth by the WHO, Medicines Patent Pool (MPP) and the NIH for COVID-19 technologies licensed globally through the WHO program.
Researchers at the Centers for Disease Control and Prevention (CDC) developed a low-cost technology to rapidly detect HIV-1 drug resistance (HIVDR) in plasma and dried blood spot (DBS) samples with 95.8% genotyping sensitivity. CDC’s partners at Life Technologies Corporation (“LifeTech”) have licensed, further developed, and incorporated the technology into a commercialized product. Life Tech’s HIV-1 Genotyping Kit provides a cost-effective assay, scalable workflow, easy-to read sequencing results, and robust test performance.
This development is the first and only FDA approved diagnostic test kit for parvovirus B19. Parvovirus B19 infection in pregnancy is often overlooked simply because most infected pregnant women are asymptomatic or have only mild manifestations, such as slight itching. However, pregnant women (in the first and second trimesters) with the B19 infection can give rise to serious fetal complications during pregnancy. Up to 50% of women are susceptible to parvovirus B19 infection. The B19 infection may result in anemia, pregnancy miscarriage and/or other problems.
This new, accelerated magnetic resonance imaging (MRI) method reduces the total imaging time for lengthy scans. The method may be used for imaging dynamic events such as heart motion or brain activity. The technology exploits the spatial and temporal correlation of magnetic resonance signals by combining parallel imaging and temporal filtering to achieve a new MRI technique referred to as (TSENSE). The TSENSE method has a higher degree of artifact suppression using parallel imaging and temporal filtering.
Most people are aware that anti-cancer treatments often have negative side effects, but patients are willing to tolerate these side effects for the potential life-saving effects of the treatment. However, some patients treated with the anti-cancer drug 5-Fluorouracil (5-FU) will have fatal reactions typically caused by cardiotoxicity. A life-saving diagnostic test to identify cancer patients who may experience 5-FU toxicity has been developed by scientists at the National Cancer Institute (NCI).
Most people are aware that anti-cancer treatments often have negative side effects, but patients are willing to tolerate these side effects for the potential life-saving effects of the treatment. However, some patients treated with the anti-cancer drug 5-Fluorouracil (5-FU) will have fatal reactions typically caused by cardiotoxicity. A life-saving diagnostic test to identify cancer patients who may experience 5-FU toxicity has been developed by scientists at the National Cancer Institute (NCI).